Pag-aaral pangklinika para sa Leukemia sa Colorado
15 pag-aaral para sa Leukemia ang naghahanap ng mga kalahok sa mga site sa Colorado.
Mga Lungsod sa Colorado
Opisyal na teksto ng pag-aaral (English)
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Colorado, Aurora
Nagre-recruitPhase 1/2
30 Days · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04065399Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Denver
Nagre-recruitPhase 3
Edad 18 hanggang 18 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07509151First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
- Children's Hospital Colorado, Aurora
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07586618Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT07007312Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Colorado Children's Hospital, Denver
Nagre-recruitPhase 2
Edad 7 hanggang 25 · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579Integrated Cancer Repository for Cancer Research
- Advent Health, Greenwood Village
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
Nagre-recruitObservasyonal na pag-aaral
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT06131801Shwachman Diamond Syndrome Registry and Study
- Children's Hospital Colorado, Aurora
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Abr 6, 2026 · NCT06056908A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT05735184Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families
- Children's Hospital Colorado, Aurora
Nagre-recruitObservasyonal na pag-aaral
Hanggang edad 22 · Lahat ng kasarian · Na-update Peb 5, 2026 · NCT05425992Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
- University of Colorado Hospital, Aurora
Nagre-recruitPhase 1
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ene 15, 2026 · NCT06429449Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Rocky Mountain Cancer Centers, Aurora
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 31, 2025 · NCT06549790SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Aurora
- Massive Bio SYNERGY-AI site, Denver
- Massive Bio SYNERGY-AI site, Littleton
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.